Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0Z2JF
|
|||
| Former ID |
DIB009436
|
|||
| Drug Name |
Nivocasan
|
|||
| Synonyms |
GS-9450; LB-84451
Click to Show/Hide
|
|||
| Indication | Fibrosis [ICD-11: GA14-GC01; ICD-10: L90.5; ICD-9: 709.2] | Phase 2 | [1] | |
| Company |
LG Life Sciences Ltd
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H22FN3O5
|
|||
| Canonical SMILES |
CC(C)C1(CC(=NO1)C2=NC=CC3=CC=CC=C32)C(=O)NC4CC(=O)OC4(CF)O
|
|||
| InChI |
1S/C21H22FN3O5/c1-12(2)20(19(27)24-16-9-17(26)29-21(16,28)11-22)10-15(25-30-20)18-14-6-4-3-5-13(14)7-8-23-18/h3-8,12,16,28H,9-11H2,1-2H3,(H,24,27)/t16-,20+,21+/m0/s1
|
|||
| InChIKey |
VYFGDLGHHBUDTQ-ZLGUVYLKSA-N
|
|||
| CAS Number |
CAS 908253-63-4
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Combined effects of an antioxidant and caspase inhibitor on the reversal of hepatic fibrosis in rats. Apoptosis. 2013 Dec;18(12):1481-91. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.